An alternative modality for the treatment of lip cancer or oral commissure cancer

An alternative modality for the treatment of lip cancer or oral commissure cancer

e226 E-Poster Presentation surgeries. The regulations for Patient specific implants production in different countries must be respected. http://dx.d...

51KB Sizes 8 Downloads 39 Views

e226

E-Poster Presentation

surgeries. The regulations for Patient specific implants production in different countries must be respected. http://dx.doi.org/10.1016/j.ijom.2015.08.128 An alternative modality for the treatment of lip cancer or oral commissure cancer Y. Hsia 1,∗ , P. Hsu 1 , S. Chang 2 1

Division of Oral Maxillofacial Surgery, Taipei Tzu Chi Hospital, New Taipei City, Taiwan 2 Division of Hematology-Oncology, Taipei Tzu Chi Hospital, New Taipei City, Taiwan Background: Lip cancer is the most common malignant tumour of the oral cavity and is the second most common cancer in head and neck, following cutaneous malignancy, and constituting 25–30% of cases. In the United States, incidence of lip cancer is about 1.8 per 100,000 population. In Australia, its incidence is as high as 13.5 per 100,000 population in males. In Taiwan, lip cancer incidence is about 1.68 per 100,000 population. 90% of lip cancer occurred on lower lip. The oral commissure is the tumour origin in 0.7% to 6.1% in all cases. Lip cancer is very common in white male smokers who are in their sixth decade of their life. In Taiwan, however, lip cancer occurred on male non-retired labours from their third decade to five decade of life. Objectives: There were 14 lip or oral commissure cancer patients in past four years. 9 out of 14 patients had treated with surgical and 4 out of 14 patients had treated with induction chemotherapy followed by surgery or CCRT. Methods: Induction chemotherapy with TPF (tarxotere, cisplatin and 5-FU) followed by surgery or CCRT. Findings and conclusions: Induction chemotherapy followed by palliative surgery or CCRT for lip cancer patients could preserve oral functional and cosmetic appearance. Patients can go back to their jobs and social life easily without any sacrifice. http://dx.doi.org/10.1016/j.ijom.2015.08.129 Piezoelectric osteotomy for vertical distraction osteogenesis of fibular bone flap in reconstructed mandible H.J. Hsu Department of Oral and Maxillo-facial Surgery of Chung-Ho Memorial Hospital, Kaohsiung Medical University in Kaohsiung, Taiwan Background: Excellent aesthetic results can be achieved in mandibular reconstructions with using free fibular bone flap. However, the vertical deficiency made dental rehabilitation impossible. To overcome this vertical distraction of the reconstructed mandible is a good treatment option. But the use of traditional instruments to perform this kind of surgery would be difficult. Objectives: The purpose of this article was to suggest the use of piezosurgery in performing distraction osteogenesis of reconstructed mandible. Methods: A 48-year-old patient had his mandible reconstructed following wide resection of an ameloblastoma. A reconstruction plate (Synthes GmbH, Oberdorf, Switzerland) was used for fixation of the fibular bone but the vertical deficiency was noted. To overcome this segmental vertical distraction of the reconstructed mandible was performed with piezoelectric surgery. Fibular bone segments (40 mm × 2 mm) were distracted with using intraoral distraction device after a latency period of

7 days. The rate of distraction was 1 mm/day, and the rhythm was 2 times (2 mm × 0.5 mm). Distraction was continued until the desired height was achieved, and the distractor left in place for 12 weeks for bony consolidation. No minor or major complications were encountered. The increase of vertical height was 12 mm, and it was stable during the follow-up period (12 months). Following the vertical distraction and vestibuloplasty operations, the dental restoration of the patients was performed with implant supported fixed partial dentures. Finding and conclusion: The use of a piezoelectric device to perform this kind of surgery provides good clinical and surgical results. http://dx.doi.org/10.1016/j.ijom.2015.08.130 The research of TRAF2 siRNA in the enhancement of radiotherapy sensitivity of the oral squamous cell carcinoma X. Huang ∗ , L. Jianhua, W. Huiming, Z. Huiyong, L. Zhiyong Department of Stomatology, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, PR China Background: Oral squamous cell carcinoma (OSCC) is one of most common malignant tumours in head and neck region. Compared to the radiotherapy and chemotherapy, the targeted therapy has made a rapid progress in recent years. Tumour necrosis factor receptor-associated factor 2 (TRAF2) plays a key role in multiple anti-apoptotic signalling pathways and has been reported highly expressed in quite a few malignant tumours. Objectives: To identify that TRAF2 is a therapeutic target for OSCC and TRAF2 siRNA can enhance the radiotherapy sensitivity of OSCC. Methods: Immunohistochemical staining was used to determine the expression of TRAF2 in 50 OSCC tissue samples, with normal oral mucosa as control. An OSCC cell line (CAL27) was transfected with TRAF2 siRNA. The CCK-8 method and the PI/Annexin V method were used to compare the cell viability and apoptotic ratio in TRAF-siRNA transfected CAL27 cells, control siRNA transfected cells and blank cells after the radiation 0 Gy, 2 Gy, 4 Gy, 6 Gy and 8 Gy, respectively. Findings: TRAF2 expression was positive in 92% of 50 OSCC samples but negative in 90% normal mucosa. Compared to the control siRNA transfected group and the blank group, the cell proliferative capacity was significantly lower and the apoptotic rate were significantly higher in the TRAF2 siRNA transfected group. Among all the different radiation doses, it was 6 Gy which most significantly increased the apoptotic ratio in the TRAF2siRNA transfected group (P < 0.05). Conclusions: TRAF2 is specifically expressed in OSCC tissue and an attractive therapeutic target for anticancer therapy and radiosensitization. http://dx.doi.org/10.1016/j.ijom.2015.08.131